Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling

Cancer Research

Volumn 72, Issue 1, 2012, Pages 201-209

  Spitzer, Dirk ^a,c   Simon, Peter O ^a   Kashiwagi, Hiroyuki ^a   Xu, Jinbin ^a   Zeng, Chenbo ^a   Vangveravong, Suwanna ^a   Zhou, Dong ^a   Chang, Katherine ^a   McDunn, Jonathan E ^a   Hornick, John R ^a   Goedegebuure, Peter ^a,b   Hotchkiss, Richard S ^a   Mach, Robert H ^a   Hawkins, William G ^a,b,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MO   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LIGAND; S2 BIM; S2 BIMX; S2 CTMP 4; S2 RAPAMYCIN; SIGMA 2 OPIATE RECEPTOR; SV 119; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; DRUG BINDING; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84855392178     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1354     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Sierzega M, Popiela T, Kulig J, Nowak K. The ratio of metastatic/ resected lymph nodes is an independent prognostic factor in patients with node-positive pancreatic head cancer. Pancreas 2006;33:240-5. (Pubitemid 44470138)
3. Linehan DC, Tan MC, Strasberg SM, Drebin JA, Hawkins WG, Picus J, et al. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study. Ann Surg 2008;248:145-51.
4. Karasek P, Skacel T, Kocakova I, Bednarik O, Petruzelka L, Melichar B, et al. Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study. Expert Opin Pharmacother 2003;4:581-6. (Pubitemid 36511986)
5. Wheeler KT, Wang LM, Wallen CA, Childers SR, Cline JM, Keng PC, et al. Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer 2000;82:1223-32. (Pubitemid 30128883)
6. Choi SR, Yang B, Plossl K, Chumpradit S, Wey SP, Acton PD, et al. Development of a Tc-99m labeled sigma-2 receptor-specific ligand as a potential breast tumor imaging agent. Nucl Med Biol 2001;28:657-66. (Pubitemid 32772868)
7. Fahy BN, Schlieman MG, Virudachalam S, Bold RJ. Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg 2004;198:591-9. (Pubitemid 38446534)
8. Flick MB, O'Malley D, Rutherford T, Rodov S, Kamsteeg M, Hao XY, et al. Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients. J Soc Gynecol Investig 2004;11:252-9. (Pubitemid 38561371)
9. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976;197:517-32.
10. Hou C, Tu Z, Mach R, Kung HF, Kung MP. Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker. Nucl Med Biol 2006;33:203-9.
11. Zeng C, Vangveravong S, Xu J, Chang KC, Hotchkiss RS, Wheeler KT, et al. Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy. Cancer Res 2007;67:6708-16. (Pubitemid 47105517)
12. Kashiwagi H, McDunn JE, Simon PO Jr, Goedegebuure PS, Xu J, Jones L, et al. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol Cancer 2007;6:48.
13. Crawford KW, Bowen WD. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res 2002;62:313-22. (Pubitemid 34074021)
14. Xu J, Zeng C, Chu W, Pan F, Rothfuss JM, Zhang F, et al. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun 2011;2:380.
15. O'Reilly LA, Cullen L, Visvader J, Lindeman GJ, Print C, Bath ML, et al. The proapoptotic BH3-only protein bim is expressed in hematopoietic, epithelial, neuronal, and germ cells. Am J Pathol 2000;157:449-61. (Pubitemid 30626908)
16. Li R, Moudgil T, Ross HJ, Hu HM. Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim. Cell Death Differ 2005;12:292-303. (Pubitemid 40360952)
17. Garber K. New apoptosis drugs face critical test. Nat Biotechnol 2005;23:409-11. (Pubitemid 41724910)
18. Kashiwagi H, McDunn JE, Goedegebuure PS, Gaffney MC, Chang K, Trinkaus K, et al. TAT-Bim induces extensive apoptosis in cancer cells. Ann Surg Oncol 2007;14:1763-71. (Pubitemid 46790997)
19. Knobbe CB, Reifenberger J, Blaschke B, Reifenberger G. Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas. J Natl Cancer Inst 2004;96:483-6. (Pubitemid 38443652)
20. Chae KS, Martin-Caraballo M, Anderson M, Dryer SE. Akt activation is necessary for growth factor-induced trafficking of functional K(Ca) channels in developing parasympathetic neurons. J Neurophysiol 2005;93:1174-82. (Pubitemid 40283709)
21. Simon PO Jr, McDunn JE, Kashiwagi H, Chang K, Goedegebuure PS, Hotchkiss RS, et al. Targeting AKT with the proapoptotic peptide, TATCTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma. Int J Cancer 2009;125:942-51.
22. Gibbons JJ, Abraham RT, Yu K. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol 2009;36 Suppl 3:S3-17.
23. Rowinsky EK. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 2004;16:564-75. (Pubitemid 39482975)
24. Hornick JR, Xu J, Vangveravong S, Tu Z, Mitchem JB, Spitzer D, et al. The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. Mol Cancer 2010;9:298.
25. Xu J, Tu Z, Jones LA, Vangveravong S, Wheeler KT, Mach RH. [3H]N- [4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl]-2-methoxy- 5 -methylbenzamide: a novel sigma-2 receptor probe. Eur J Pharmacol 2005;525:8-17. (Pubitemid 41689015)
26. Vangveravong S, Xu J, Zeng C, Mach RH. Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl carbamate analogs as sigma2 receptor ligands. Bioorg Med Chem 2006;14:6988-97. (Pubitemid 44307642)
27. Ostenfeld MS, Fehrenbacher N, Hoyer-Hansen M, Thomsen C, Farkas T, Jaattela M. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res 2005;65:8975-83. (Pubitemid 41377389)
28. Zeng C, Vangveravong S, Jones LA, Hyrc K, Chang KC, Xu J, et al. Characterization and evaluation of two novel fluorescent sigma-2 receptor ligands as proliferation probes. Mol Imaging. 2011 Apr 27. [Epub ahead of print].
29. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP Jr, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/ 6 mice. Cancer Res 1984;44:717-26. (Pubitemid 14184610)
30. High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, Khaw SL, et al. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol 2010;77:483-94.
31. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-8.
32. Chonghaile TN, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene 2008;27 Suppl 1:S149-57.